Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Wednesday, April 29, 2009 - 08:28
in Health & Medicine
Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.
Read the whole article on Physorg
More from Physorg
Related
- Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancerWed, 29 Apr 2009, 9:09:30 EDT
- Vitamin E, selenium and soy in combination does not prevent prostate cancerSun, 26 Apr 2009, 9:25:21 EDT
- Men treated for localized prostate cancer could benefit from pomegranate juice consumptionSun, 26 Apr 2009, 9:25:18 EDT
- Radiation added to hormone therapy increases survival for men with prostate cancerMon, 22 Sep 2008, 8:29:41 EDT
- Survival predictors may help customize treatment options for men with metastatic prostate cancerThu, 14 May 2009, 19:08:20 EDT